'Buyer Beware?' | GenomeWeb

'Buyer Beware?'

The Motley Fool's Brian Orelli this week calls genome sequencing "the world's best innovation that isn't worth investing in." Orelli says that he sees "little reason to invest in the genome sequencing industry," particularly because "what's great for the end users isn't necessarily great for those producing the tools."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.